Investors are going crazy for shares in hearing implant provider Cochlear Limited (ASX: COH), pushing the company’s share price up 21% so far in 2016.

So what’s all the fuss about?

Part of the appeal is undoubtedly the growing recognition that healthcare stocks have been a great way to earn returns above the bank laden S&P/ASX 200 (Index: ^AXJO) (ASX: XJO).

Cochlear is included in the strong performing S&P/ASX 200 Health Care Index (Index: ASX: XHJ) along with CSL Limited (ASX: CSL) and Fisher & Paykel Healthcare Corp Ltd (ASX: FPH), which have also been exceptional performers over 2016.

But the real attraction is the business itself. By its own estimates Cochlear is the global leader in implantable hearing solutions and is insulated from competition by a “comprehensive” portfolio of patents.

Enviable returns

Not only is the company growing sales revenue consistently, but the margins it can derive off its products are enviable. In the 2015 financial year Cochlear’s net profit margin was 15.7%, but the company also achieved a massive return on equity (ROE) of 41%.

Return on equity is essential for investors. It divides net income by shareholder equity and reflects the return the company generates on shareholder funds. If sustainable, high returns can be invested back into the company to be compounded for years to come.

Cochlear’s ROE was up considerably from 2014 when net profit was hit by higher costs and a provision for a patent dispute. By comparison, fellow heath care index company Ansell Limited (ASX: ANN) reported a ROE of 16%.

Cochlear’s capital structure does include a fair amount of debt to push this figure up, with a debt-to-equity ratio of around 1.4x, but this is similar to CSL Limited and seems appropriate for the company’s strong competitive position.

Should you join the party?

With a current trailing price-to-earnings ratio of 38, compared to the Health Care Index’s 23.3, investors are certainly pricing in a lot of optimism.

However, Cochlear is expecting sustained long-term growth and certainly has a lot of attractive characteristics. Not only does the company help to massively improve patients’ quality of life, but it is globally diverse and produces huge returns for investors.

If the high returns can be maintained and the company has stringent product quality focus, Cochlear in my view has the potential to continue to compound and deliver value for investors in the years ahead.

But Cochlear has nothing on these 3 Blue Chip companies!

Discover The Motley Fool's top 3 blue chips for 2016. These 3 'new breed' shares pay fully franked dividends AND offer the very real prospect of significant capital appreciation. Simply click here to gain access to this comprehensive FREE investment report.

 

No credit card required.

HOT OFF THE PRESSES: Motley Fool’s #1 Dividend Pick for 2017!

With its shares up 155% in just the last five years, this ‘under the radar’ consumer favourite is both a hot growth stock AND our expert’s #1 dividend pick for 2017. Now we’re pulling back the curtain for you... And all you have to do to discover the name, code and a full analysis is enter your email below!

Simply enter your email now to receive your copy of our brand-new FREE report, “The Motley Fool’s Top Dividend Stock for 2017.”

By clicking this button, you agree to our Terms of Service and Privacy Policy. We will use your email address only to keep you informed about updates to our website and about other products and services we think might interest you. You can unsubscribe from Take Stock at anytime. Please refer to our https://www.fool.com.au/financial-services-guide">Financial Services Guide (FSG) for more information.

Motley Fool contributor Regan Pearson has no position in any stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.